Physician profile
Anne E Callahan
NPI 1891082483
$30,401.30
in general payments reported to CMS, 2019-2025
23 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,287 · 2022: $12K · 2023: $15K · 2024: $105 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,171 · Travel and Lodging: $2,061 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,550.00 |
| Food and Beverage | $2,170.61 |
| Travel and Lodging | $2,060.93 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16,045.84 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $10,528.53 | 2021-2023 | Dupixent |
| Abbvie INC. | $976.25 | 2021-2025 | |
| Incyte Corporation | $567.93 | 2021-2023 | Opzelura |
| Almirall LLC | $273.82 | 2021-2023 | Seysara |
| Revance Therapeutics, INC. | $255.47 | 2025 | Daxxify |
| Janssen Biotech, INC. | $208.14 | 2021-2023 | Remicade, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $170.87 | 2021-2024 | |
| Regeneron Pharmaceuticals, INC. | $155.35 | 2021-2023 | Dupixent |
| Amgen INC. | $143.82 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $133.70 | 2021-2022 | |
| Pfizer INC. | $127.81 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $112.33 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $111.97 | 2021 | |
| Leo Pharma INC. | $105.15 | 2022-2023 | Adbry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $102.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $87.42 | 2021-2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $83.39 | 2023 | |
| Mayne Pharma Commercial LLC | $60.54 | 2021 | |
| Dermavant Sciences, INC. | $54.40 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $38.67 | 2021 | |
| Janssen Scientific Affairs, LLC | $30.68 | 2021 | |
| Epi Health, LLC | $26.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.